Peer Review reports
From: CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth
| Original Submission | ||
|---|---|---|
| 24 Nov 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 6 Jan 2023 | Reviewed | Reviewer Report |
| 10 Feb 2023 | Reviewed | Reviewer Report |
| 8 Mar 2023 | Reviewed | Reviewer Report |
| 8 May 2023 | Author responded | Author comments - Qian-Qian Zhang |
| Resubmission - Version 3 | ||
| 8 May 2023 | Submitted | Manuscript version 3 |
| 9 May 2023 | Author responded | Author comments - Qian-Qian Zhang |
| Resubmission - Version 4 | ||
| 9 May 2023 | Submitted | Manuscript version 4 |
| 10 May 2023 | Author responded | Author comments - Qian-Qian Zhang |
| Resubmission - Version 5 | ||
| 10 May 2023 | Submitted | Manuscript version 5 |
| 10 May 2023 | Author responded | Author comments - Qian-Qian Zhang |
| Resubmission - Version 6 | ||
| 10 May 2023 | Submitted | Manuscript version 6 |
| Publishing | ||
| 16 May 2023 | Editorially accepted | |
| 26 May 2023 | Article published | 10.1186/s12885-023-10974-4 |
You can find further information about peer review here.